BARNSTABLE, MA September 19, 2013 -- UV Flu Technologies, Inc. (OTCQB: UVFT) (the “Company”) announced today that the warning issued this week from the CDC, or Center for Disease Control, relating to the threats from strains of bacteria that have grown impervious to bacteria, may only scratch the surface with respect to the overall threat. The health warning did estimate that at least 2 million people in this country become infected with bacteria that are resistant to antibiotics, and that at least 23,000 people die each year as a result of these infections. Thousands more die from infections contracted in hospitals, as well as from other conditions that were complicated by antibiotic-resistant infections.
“We feel the problem is getting worse, not better,” said Jack Lennon, President of UV Flu Technologies, the manufacturer of the ViraTech UV-400, an FDA cleared air purifier which kills over 99% of airborne bacteria with every pass.
“The average person breathes 3,600 gallons of air per day, and little if any has been treated to kill or trap the airborne infection and contaminants that enter our lungs every minute we’re alive. TB, Whooping Cough, MRSA, Staph, and a host of other airborne bacteria and viruses are growing stronger, in some cases becoming totally resistant to treatment with antibiotics. Many of these strains are at epidemic proportions in other countries, and its’ only a matter of time before they spread to this country,” said Mr. Lennon.
“Children experience antibiotics at much earlier ages, rarely have the childhood diseases that most adults had 30-50 years ago, and they spend 90% of their time indoors, so their immune response systems are at a disadvantage in fighting off these resistant strains of bacteria and other contaminants. This combination could have deadly consequences in the future. A small contraction in the breathing passages of small children can cut their breathing 60-70%, up to 4 times more severe than a typical adult.”
“We feel preventing the spread of these airborne infections is the first line of defense. Airborne contaminants sink over time, making surface contamination more severe, so just wiping down surfaces only addresses part of the problem.”
Dr. Walter Kowalski, one of the worlds’ leading authorities on ultraviolet light, and its ability in killing organic contaminants, in a report issued in June, 2013, evaluated the ViraTech UV-400 Portable Air Purification Unit, and how effective it was in utilizing 3 UV lamps and a catalytic kill chamber, with the purpose of stopping the spread of airborne infection. After evaluating dozens of competing units, Dr. Kowalski said, “Considering the ability of the UV-400 to kill all bacteria, viruses, and fungal spores in a typical sized room, it is clearly among the “Best in Class” of all devices evaluated.
Further details regarding the Company’s business, acquisitions, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database. For more information, visit: www.uvflutech.com, and click on the 5 minute video describing the ViraTech UV-400[TM].
About UV Flu Technologies, Inc. (OTCQB: UVFT)
UV Flu Technologies is an innovative developer; manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector ($7 billion in 2011). The Company manufactures the ViraTech UV-400[TM], which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC’s (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit:www.uvflutech.com.
About RxAir Industries, LLC
RxAir[TM] is the leading provider of air purification solutions for the medical industry with hundreds of units in waiting rooms to emergency rooms in respected medical facilities nationwide. RxAir™ products remove harmful pathogens from the air in infectious environments for emergency pandemics through isolation rooms and negative pressure rooms. The RxAir™ air purification line is 99.97% efficient, portable, and adaptable, requires zero-maintenance. http://www.rxair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. Executing the transaction requires further work on structure, management, governance, and other significant matters. Within the next number of months, UV Flu’s and RxAir’s management will develop detailed plans for the Board's further consideration and final approval.
The completion of the spin-off is subject to a number of conditions, including final approval of the transaction by each Board, favorable tax rulings and or opinions of the transaction to UV Flu and to its shareholders, further due diligence as appropriate, and the filing and effectiveness of appropriate filings with the Securities and Exchange Commission (“SEC”). There can be no assurances given that the separation of UV Flu’s business as described in this announcement will occur. UV Flu will provide interim updates as appropriate.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President/CEO
Toll-Free: 1-877-358-5545 (FLU-KILL)
Retail or Internet Inquires:
Please call our Corporate Office at: 508-362-5455
SOURCE UV Flu Technologies, Inc.